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Summary
Background: Older age and comorbidities are the main risk factors for adverse 
COVID- 19 outcomes in patients with inflammatory bowel disease (IBD). The impact 
of IBD medications is still under investigation.
Aims: To assess risk factors for adverse outcomes of COVID- 19 in IBD patients and 
use the identified risk factors to build risk indices.
Methods: Observational cohort study. Univariable and multivariable logistic regres-
sion was used to identify risk factors associated with pneumonia, hospitalisation, 
need for ventilatory support, and death.
Results: Of the 937 patients (446 with ulcerative colitis [UC]) evaluated, 128 (13.7%) 
had asymptomatic SARS- CoV- 2 infection, 664 (70.8%) had a favourable course, 
and 135 (15.5%) had moderate or severe COVID- 19. In UC patients, obesity, active 
disease and comorbidities were significantly associated with adverse outcomes. In 
patients with Crohn's disease (CD), age, obesity, comorbidities and an additional 
immune- mediated inflammatory disease were identified as risk factors. These risk 
factors were incorporated into two indices to identify patients with UC or CD with a 
higher risk of adverse COVID- 19 outcomes. In multivariable analyses, no single IBD 
medication was associated with poor COVID- 19 outcomes, but anti- TNF agents were 
associated with a lower risk of pneumonia in UC, and lower risks of hospitalisation 
and severe COVID- 19 in CD.
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1  | BACKGROUND
Over the past year, severe acute respiratory syndrome coronavirus 
2 (SARS- CoV- 2) has rapidly spread around the world.1 Research 
into the pathology of SARS- CoV- 2- induced coronavirus disease 
2019 (COVID- 19) has revealed that the immune system plays two 
crucial roles in the infection: it controls viral replication in the early 
stage, and it overproduces pro- inflammatory cytokines in patients 
who go on to develop severe disease.2 Thus, physicians who care 
for patients with immune- mediated inflammatory diseases (IMID) 
are concerned about the impact that COVID- 19 could have on 
these patients.
Like all IMIDs, the two main types of inflammatory bowel 
disease (IBD), namely ulcerative colitis (UC) and Crohn's disease, 
are characterised by an abnormal functioning of the innate and 
adaptive immune systems, leading to a chronic, progressive condi-
tion. From emerging data, the incidence and prevalence of SARS- 
CoV- 2 infection in IBD patients are not different from those in 
the general population.3- 7 Additionally, the prevalence of adverse 
COVID- 19 outcomes, namely pneumonia, hospitalisation, inten-
sive care unit admission and death, appears to be similar to that 
in the general population.4- 9 Numerous studies that investigated 
risk factors for adverse COVID- 19 outcomes in IBD patients con-
cordantly found similarities with those in the general population, 
namely older age6- 12 and presence of comorbidities.3,6,8- 10,12,13 
However, in the assessment of IBD- related factors, discordant 
results were obtained. For example, some studies reported that 
disease activity was a risk factors for adverse outcomes of SARS- 
CoV- 2 infection,9,12 while other studies identified treatment with 
corticosteroids,8,11,14 aminosalicylates,11,13 and thiopurines (alone 
or in combination with anti- TNF- α agents)13 as risk factors. These 
discrepancies may be due to insufficient numbers of cases or dif-
ferences in epidemiological methodology.
The ongoing SARS- CoV- 2 vaccination program has also raised 
an important clinical question about the eligibility of IBD patients 
for priority access to primary vaccination and booster doses. On 
one hand, this decision could be supported by evidence of a lower 
serological response to vaccines or natural infection, related to 
either IBD itself15 or IBD therapies, namely anti- TNF agents.16,17 
On the other hand, if priority access is granted to people at higher 
risk of adverse COVID- 19 outcomes, should this apply to some 
or all IBD patients? To answer this question, this observational 
study investigated risk factors for adverse COVID- 19 outcomes 
in a large, nation- wide cohort of IBD patients, and used multivari-
able analyses to build indices to identify patients at the relatively 
highest risk.
2  | METHODS
This observational cohort study was supported by the Italian Group 
for the Study of Inflammatory Bowel Disease (IG- IBD). The pri-
mary objective was to identify risk factors for adverse outcomes 
of COVID- 19 in IBD patients. The secondary objective was to 
develop an index to identify IBD patients at increased risk of se-
vere COVID- 19. The study protocol was approved by the IG- IBD 
Scientific Committee and the Coordinating Ethical Committee of 
ASST Rhodense. All 96 IBD centres affiliated with IG- IBD were in-
vited to participate in the study.
Patients at participating IBD centres were consecutively in-
cluded in this study if they had an established diagnosis of Crohn's 
disease (CD) or UC for at least 6 months and confirmed SARS- 
CoV- 2 infection plus follow- up for at least 1 month. A confirmed 
SARS- CoV- 2 infection was defined as either the polymerase chain 
reaction- confirmed presence of SARS- CoV- 2 genome in a nasopha-
ryngeal swab or the ELISA- confirmed presence of anti- SARS- CoV- 2 
spike protein antibodies in serum, or both. Data collection was done 
from March 11 to December 31, 2020.
For all patients, the following data were collected from medi-
cal charts and, when possible, patient interviews: age, sex, current 
smoking habit (yes or no), IBD type, IBD duration, IBD activity 
(classified as in remission, mild, moderate or severe according to 
the partial Mayo score for UC18 and the Harvey- Bradshaw index 
for CD19) in the 3 months before the diagnosis of SARS- CoV- 2 in-
fection, IBD treatments, comorbidities (including other concom-
itant IMIDs), Charlson's comorbidity index (CCI),20 symptoms of 
SARS- CoV- 2 infection and COVID- 19 outcome (favourable, mod-
erate or severe). Symptoms of COVID- 19 were classified as: gas-
trointestinal (diarrhoea, nausea or abdominal pain), systemic (fever, 
arthralgia, myalgia, asthenia or hyporexia), respiratory (pharyngo-
dynia, cough, rhinitis and dyspnoea) and dysgeusia or anosmia. A 
moderate COVID- 19 outcome was defined as a diagnosis of pneu-
monia (demonstrated by chest CT or radiography) or the need for 
hospitalisation, while a severe outcome was defined as ventilatory 
assistance use (continuous positive airway pressure, non- invasive 
mechanical ventilation or intubation) or death. These data were 
Conclusion: The course of COVID- 19 in patients with IBD is similar to that in the 
general population. IBD patients with active disease and comorbidities are at greater 
risk of adverse COVID- 19 outcomes. IBD medications do not pose additional risks. 
The risk indices may help to identify patients who should be prioritised for COVID- 19 
re- vaccination or for therapies for SARS- CoV- 2 infection.
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entered into an electronic database accessible to participating 
centres.
2.1 | Statistical analysis
Analyses were conducted using SPSS Statistical Software (v. 13.0, 
IBM). Differences in quantitative variables at baseline between 
UC and CD patients were tested for significance using the t test. 
Associations between the type of IBD and categorical variables 
(baseline characteristics and symptoms of COVID- 19) were tested 
for significance using the chi- square test. A two- tailed P < 0.05 was 
indicative of statistical significance.
Risk factors for moderate- to- severe COVID- 19 outcomes were 
identified by logistic regression with univariable and multivariable 
analyses. Multivariable analyses were adjusted for confounding fac-
tors that could simultaneously impact upon another variable and the 
outcome (eg elderly patients are uncommonly prescribed anti- TNF 
agents, so the use of these drugs was adjusted for age). Confounding 
factors were selected according to the literature3- 14 and to reports by 
the Italian national health service on causes of death from COVID- 19 
in the general population and in IBD patients.21 The confounding fac-
tors selected to adjust the regression analyses were therefore age, 
comorbidities, IMID and disease activity. Logistic regression was also 
used to assess the impact of medications on COVID- 19 outcomes.
Variables that were retained in the multivariable analyses at 
P < 0.05 were used to build an index for the risk of moderate- to- severe 
COVID- 19 in IBD patients. The coefficients from the multivariable anal-
ysis were used to assess the weight of each variable retained in the 
model and to calculate the index. We tested the sensitivity, specificity, 
and positive and negative likelihood ratios of this index using the clinical 
data from our population. ROC curve analysis was used to set the most 
sensitive and specific cut- off to identify IBD patients with infection by 
SARS- CoV- 2 at risk of moderate- to- severe COVID- 19.
3  | RESULTS
We enrolled 937 IBD patients with a confirmed SARS- CoV- 2 in-
fection (Table 1) from 47 centres. The study group comprised 446 
patients with UC (47.6%) and 491 with CD (52.4%), including 79 
patients whom we had already studied.9 The UC and CD groups 
differed significantly for age (CD patients were younger), disease 
activity, and therapies, with salicylates and vedolizumab used more 
frequently by UC patients and TNF antagonists and ustekinumab 
used more frequently by CD patients. At least one comorbidity was 
present in 376 (40.1%) IBD patients [89 (9.5%) had arterial hyperten-
sion and 21 were obese (2.2%)]; 116 patients (12.4%) had an IMID 
other than IBD.
Overall, 809 patients (86.3%) had symptomatic SARS- CoV- 2 in-
fection, including 392 UC patients (87.9% of all UC patients) and 417 
CD patients (84.9%) (Table S1). The most prevalent class of symp-
toms was respiratory, registered in 60.8% of UC patients and 48.9% 
of CD patients. The least prevalent class of symptoms was gastroin-
testinal in both groups. A favourable course of infection with symp-
toms resolution was recorded in 664 cases (70.8%).
For the IBD patients with moderate or severe outcomes of 
COVID- 19, 145 (15.5%) had pneumonia, 130 (13.9%) required 
hospitalisation, 65 (6.9%) required ventilatory support, and 25 
(2.7%) died. The rates of all adverse COVID- 19 outcomes, but 
death, were significantly higher in UC patients than in CD pa-
tients (Figure S1).
3.1 | Risk factors for moderate or severe 
COVID- 19 outcomes
In UC patients, the variables found to be predictive of moderate or 
severe outcomes at univariable analysis were age (per unit increase, 
P < 0.001), active disease of any severity (P = 0.001), obesity (P < 0.001), 
arterial hypertension (P = 0.01), and CCI (per unit increase, P < 0.001) 
(Table S2). At multivariable analysis, active disease (P < 0.001), obesity 
(P < 0.001), and CCI (P < 0.001) were significantly associated with a 
moderate or severe outcome. Univariable analyses in CD patients iden-
tified age (P < 0.001), obesity (P = 0.008), IMID (P < 0.001), and CCI 
(P < 0.001) as associated with moderate or severe outcomes, while mul-
tivariable analysis indicated age (P = 0.01), obesity (P = 0.02), and IMID 
(P = 0.01).
Regression analyses were repeated looking specifically at the 
risk of COVID- 19- related pneumonia (Table 2). For UC patients, 
univariable analyses identified age ≥60 years, active disease of any 
severity, obesity, hypertension and CCI ≥2 as associated with the 
risk of pneumonia, and multivariable analyses found that active dis-
ease (OR = 1.88), obesity (OR = 23.76), and CCI ≥2 were associated 
with the risk of pneumonia. For CD patients, age ≥60 years, obesity, 
concomitant IMID, and a CCI ≥2 were significantly associated with 
pneumonia in the univariable analysis, whereas in the multivariable 
analysis only obesity (OR = 6.54) and concomitant IMID (OR = 3.52) 
were associated with the risk of pneumonia.
Regarding hospitalisation (Table 2), in UC patients, age ≥60 years, 
active disease of any severity, obesity, hypertension and CCI ≥2 
were found to be associated with risk in univariable analyses. In 
multivariable analyses adjusted for confounders, only active disease 
(OR = 1.92), obesity (OR = 22.8) and CCI ≥2 points (OR = 3.97) were 
found to be associated with the risk of hospitalisation. In CD patients, 
age ≥60 years, obesity, a concomitant IMID and CCI ≥2 were signifi-
cantly associated with hospitalisation at the univariable analysis; at 
the multivariable analysis adjusted for confounders, only concomi-
tant IMID (OR = 2.26) was found to be associated with the risk of 
hospitalisation.
A final analysis investigated the risk of severe COVID- 19 out-
comes (need for ventilatory support or death; Table 2). In UC 
patients, age ≥60 years, male sex, active disease of any severity, 
obesity, hypertension and CCI ≥2 were found to be associated with 
the risk of severe COVID- 19; at the multivariable analyses adjusted 
for confounders, age ≥60 years (OR = 2.57), male sex (OR = 2.85), 
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active disease (OR = 2.03), obesity (OR = 20.34), and CCI ≥2 
(OR = 1.53) were associated with the risk of severe COVID- 19. 
In CD patients, age ≥60 years, obesity and CCI ≥2 were signifi-
cantly associated with severe COVID- 19 at univariable analyses; 
at multivariable analyses adjusted for confounders, only obesity 
(OR = 12.07) and CCI ≥2 (OR = 1.77) were associated with the risk 
of severe COVID- 19.
3.2 | Impact of medications on COVID- 19 outcomes
These results are shown in Table 3.
In the UC population, at univariable analysis, the use of anti- TNF 
agents was associated with significantly lower risks of COVID- 19, pneu-
monia, and severe COVID- 19. Similarly, in CD patients, the use of anti- 




(n = 446) CD (n = 491) P value
Age, years, median (range) 44 (10- 86) 47 (10- 86) 43 (12- 84) <0.001
Age ≥60 years, n (%) 185 (19.7) 106 (23.7) 75 (15.2) 0.003
Males, n (%) 513 (54.7) 252 (56.5) 261 (53.1) 0.43
Current smokers, n (%) 148 (15.8) 59 (13.2) 89 (18.1) 0.05
Disease duration, years, median (range) 11 (0- 71) 11 (0- 61) 11 (0- 71) 1.00
Disease activity, n (%)
Remission 559 (59.6) 254 (56.9) 305 (62.1) 0.002
Mild 211 (22.5) 99 (22.1) 112 (22.8) 0.002
Moderate 124 (13.2) 63 (14.1) 61 (12.4) 0.89
Severe 41 (4.3) 20 (4.4) 21 (4.2) 1.00
Therapy, n (%)a
None 56 (6.0) 20 (4.4) 36 (7.3) 0.11
Salicylates 492 (52.5) 333 (74.6) 159 (32.3) <0.001
Corticosteroids 122 (13.0) 70 (15.6) 52 (10.5) 0.04
Immunomodulators 101 (11.2) 47 (10.5) 54 (10.9) 0.75
TNF antagonists 346 (36.9) 114 (25.5) 232 (47.2) <0.001
TNF antagonists + immunomodulators 22 (2.3) 9 (2.0) 13 (2.6) 0.61
Vedolizumab 115 (12.3) 71 (15.9) 44 (8.9) <0.001
Ustekinumab 51 (5.4) 4 (0.9) 47 (9.5) <0.001
Other 13 (1.4) 8 (1.7) 5 (1.0) 0.50
Comorbidities, n (%) 376 (40.1) 188 (42.1) 188 (38.2) 0.32
IMID 116 (12.4) 47 (10.5) 69 (14.1) 0.11
Arterial hypertensionb 89 (9.5) 55 (12.3) 34 (6.9) 0.01
Obesityc 21 (2.2) 12 (2.6) 9 (1.8) 0.55
Charlson's comorbidity index, n (%)
0 538 (57.4) 234 (52.5) 311 (63.3) <0.001
1 178 (20.7) 96 (21.5) 84 (17.1) 0.34
2 102 (21.9) 57 (12.8) 68 (13.8) 0.08
3 59 (6.2) 32 (7.2) 27 (5.4) 0.06
4 18 (1.9) 9 (2.0) 9 (1.8) 0.05
5 15 (1.6) 10 (2.2) 5 (1.0) 0.25
6 9 (0.9) 6 (1.3) 3 (0.6) 0.21
7 1 (0.1) 1 (0.2) 0 (0) 1.00
8 1 (0.1) 1 (0.2) 0 (0) 1.00
Abbreviations: CD, Crohn's disease; IMID, immune- mediated inflammatory disease; UC, ulcerative 
colitis.
aThe data reflect the fact that some patients were taking more than one therapy simultaneously.
bDefined as >140/90 mm Hg.
cBody mass index >30 kg/m2.
TA B L E  1   Baseline characteristics of 
IBD patients with SARS- CoV- 2 infection
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TA B L E  2   Risk factors for COVID- 19- related pneumonia, hospitalisation and severe outcomesa in IBD patients
Univariable Multivariable
OR 95% CI P value OR 95% CI P value
Pneumonia
Ulcerative colitis
Age ≥60 years 4.66 2.85- 7.61 <0.001 — — — 
Male sex 1.17 0.76- 1.81 0.47 — — — 
Current smoking 1.47 0.78- 2.75 0.22 — — — 
Active disease (any severity) 1.76 1.11- 2.78 0.01 1.88 1.12- 3.13 <0.001
Obesity 20.83 4.48- 96.86 <0.001 23.76 4.67- 120.6 <0.001
Arterial hypertension 2.22 1.20- 40.9 0.01 — — — 
IMID 1.01 0.48- 2.12 0.97 — — — 
CCI ≥2 5.93 3.63- 9.68 <0.001 5.76 2.04- 16.31 <0.001
Crohn's disease
Age ≥60 years 3.76 2.00- 7.05 <0.001 — — — 
Male sex 0.77 0.43- 1.37 0.38 — — — 
Current smoking 0.69 0.30- 1.59 0.39 — — — 
Active disease (any severity) 1.23 0.90- 1.67 0.18 — — — 
Obesity 7.40 1.92- 28.52 0.003 6.54 1.48- 28.85 0.01
Arterial hypertension 1.96 0.77- 4.99 0.15 — — — 
IMID 3.45 1.82- 6.52 <0.001 3.52 1.81- 6.87 <0.001
CCI ≥2 3.82 2.07- 7.08 <0.001
Hospitalisation
Ulcerative colitis
Age ≥60 years 5.32 3.20- 8.84 <0.001 — — — 
Male sex 1.21 0.77- 1.92 0.40 — — — 
Current smoking 1.11 0.56- 2.21 0.93 — — — 
Active disease (any severity) 1.76 1.09- 2.84 0.01 1.92 1.12- 3.31 0.01
Obesity 24.32 5.22- 113.3 <0.001 22.8 4.40- 118.9 <0.001
Arterial hypertension 2.39 1.28- 4.46 0.006 — — — 
IMID 0.87 0.39- 1.94 0.73 — — — 
CCI ≥2 6.59 3.95- 10.99 <0.001 3.97 1.34- 11.77 0.01
Crohn's disease
Age ≥60 years 4.51 2.36- 8.62 <0.001 — — — 
Male sex 1.40 0.76- 2.56 0.28 — — — 
Current smoking 0.94 0.42- 2.10 0.89 — — — 
Active disease (any severity) 1.52 0.82- 2.80 0.17 — — — 
Obesity 5.10 1.23- 21.13 0.02 — — — 
Arterial hypertension 1.74 0.64- 4.76 0.27 — — — 
IMID 2.30 1.15- 4.60 0.01 2.26 1.09- 4.67 0.02
CCI ≥2 4.19 2.21- 7.92 <0.001 — — — 
Severe outcomes
Ulcerative colitis
Age ≥60 years 5.44 2.96- 9.99 <0.001 2.57 1.00- 6.60 0.04
Male sex 1.92 1.04- 3.57 0.03 2.85 1.35- 6.00 0.005
Current smoking 1.47 0.67- 3.22 0.32 — — — 
Active disease (any severity) 1.78 0.99- 3.21 0.049 2.03 1.03- 3.97 0.03
(Continues)
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pneumonia, hospitalisation, and severe COVID- 19. In contrast, in CD 
patients, the use of salicylates was associated with higher risks of 
COVID- 19 symptoms, pneumonia, hospitalisation and severe outcomes. 
The other medications did not have any impact on COVID- 19 outcomes.
After adjusting for confounding factors, at multivariable anal-
yses, the use of anti- TNF agents remained significantly associated 
with a lower risk of pneumonia in UC patients (OR = 0.44; 95% CI, 
0.22- 0.86) and with lower risks of hospitalisation (OR = 0.46; 95% 
CI, 0.23- 0.92) and severe COVID- 19 (OR = 0.31; 95% CI, 0.11- 0.88) 
in CD patients. Salicylates were not confirmed to be associated with 
the risk of adverse outcomes in CD patients.
3.3 | Risk assessment for moderate- severe 
COVID- 19 in IBD patients
Based on the multivariable analyses for moderate- severe COVID- 19 
outcomes, we built two risk indices that sum the contributions of 
Univariable Multivariable
OR 95% CI P value OR 95% CI P value
Obesity 12.49 3.77- 40.75 <0.001 20.34 4.83- 85.6 0.01
Arterial hypertension 2.19 1.04- 4.58 0.03 — — — 
IMID 0.49 0.14- 1.66 0.25 — — — 
CCI ≥2 6.23 3.36- 11.55 <0.001 1.53 1.17- 1.99 0.001
Crohn's disease
Age ≥60 years 5.90 2.57- 13.84 <0.001 — — — 
Male sex 1.36 0.59- 3.12 0.46 — — — 
Current smoking 0.39 0.09- 1.72 0.21 — — — 
Active disease (any severity) 1.63 0.72- 3.72 0.23 — — — 
Obesity 10.97 2.56- 46.94 0.001 12.07 2.51- 58.01 0.002
Arterial hypertension 2.91 0.93- 9.06 0.06 — — — 
IMID 2.29 0.91- 5.73 0.07 — — — 
CCI ≥2 5.06 2.19- 11.69 <0.001 1.77 1.18- 2.65 0.005
Abbreviations: CCI, Charlson's comorbidity index; CI, confidence interval; IMID, immune- mediated inflammatory disease; OR, odds ratio.
aVentilatory assistance or death.
TA B L E  2   (Continued)
TA B L E  3   Impact of IBD medications on SARS- CoV- 2 infections in IBD patients
OR (95% CI)a
Symptomsb Pneumonia Hospitalisation Severe COVID- 19c
Univariable analysis
Ulcerative colitis
TNF antagonists 0.51 (0.28- 0.90) 0.39 (0.20- 0.73) — 0.34 (0.14- 0.84)
Crohn's disease
TNF antagonists 0.43 (0.24- 0.78) 0.38 (0.20- 0.73) 0.41 (0.21- 0.80) 0.28 (0.10- 0.76)
Salicylates 2.16 (1.25- 3.74) 2.16 (1.20- 3.89) 2.44 (1.32- 4.52) 2.78 (1.21- 6.37)
Multivariable analysis
Ulcerative colitis
TNF antagonists — 0.44 (0.22- 0.86) — — 
Crohn's disease
TNF antagonists — — 0.46 (0.23- 0.92) 0.31 (0.11- 0.88)
Salicylates — — — — 
aOnly significant results (univariable analysis, P < 0.05) are reported.
bAny symptoms of COVID- 19.
cVentilatory support or death.
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significant variables. For UC patients, the index was calculated with 
the formula (where yes = 1 and no = 0):
ROC curve analysis (Figure 1A) identified a cut- off ≥0.90 for in-
creased risk of any adverse outcome of SARS- CoV- 2 (area under the 
curve [AUC] = 0.79; 95% CI, 0.75- 0.83), with 0.71 sensitivity (95% 
CI, 0.61- 0.80), 0.74 specificity (95% CI, 0.69- 0.79), a positive like-
lihood ratio (+LR) of 2.79, and a negative likelihood ratio (−LR) of 
0.39. The same cut- off was found to be the best predictor for the 
risk of pneumonia (AUC = 0.79; 95% CI, 0.75- 0.83), hospitalisation 
(AUC = 0.81; 95% CI, 0.77- 0.85), and severe COVID- 19 (AUC = 0.80; 
95% CI, 0.76- 0.84).
For CD patients, the index was calculated with the formula 
(where yes = 1 and no = 0):
ROC curve analysis for CD patients identified a cut- off ≥2.20 for 
increased risk of any adverse outcome of SARS- CoV- 2 (AUC = 0.76; 
95% CI, 0.72- 0.80), with 0.71 sensitivity (95% CI, 0.58- 0.82), 
0.69 specificity (95% CI, 0.64- 0.73), +LR = 2.31, and – LR = 0.41 
(Figure 1B). A score of ≥2.50 was the best predictor for the risk 
of pneumonia (AUC = 0.76; 95% CI, 0.72- 0.80) and hospitalisation 
(AUC = 0.77; 95% CI, 0.73- 0.80), whereas a score ≥2.44 was the best 
predictor for severe COVID- 19 (AUC = 0.78; 95% CI, 0.74- 0.81).
4  | DISCUSSION
In this study, the majority of IBD patients had an asymptomatic 
(13.7%) or favourable course (70.8%) of SARS- CoV- 2 infection. 
However, UC patients were more likely than CD patients to have 
symptoms and to develop moderate or severe COVID- 19. Among the 
145 patients who had moderate or severe COVID- 19, age ≥60 years, 
male sex, obesity, arterial hypertension and another concomitant 
IMID were risk factors for an adverse outcome. Considering varia-
bles related to IBD, disease activity of any severity was an additional 
risk factor, but no single IBD medication was found at multivariable 
analysis to be associated with adverse COVID- 19 outcomes. On the 
contrary, anti- TNF agents were associated with a lower risk of pneu-
monia in UC patients and with lower risks of hospitalisation and se-
vere COVID- 19 in CD patients.
Overall, our findings confirm that the course of COVID- 19 in 
IBD patients is similar to that observed in the general population.3- 7 
Moreover, they confirm that the general risk factors for worse out-
comes of COVID- 19 (age, male sex and comorbidities) in IBD patients 
are similar to those in the general population, as already observed 
in other studies of IBD patients.3- 14 Among IBD- related risk factors, 
the finding of a negative role of disease activity agrees with previ-
ously reported studies.9,12
Understanding if IBD therapies affect the evolution of SARS- 
CoV- 2 infection is crucial because of the possible consequences on 
the management of these patients. Indeed, stopping, postponing or 
avoiding therapies due to the fear of a negative impact on the infec-
tion could lead to IBD flares with detrimental consequences. This 
study found that patients taking anti- TNF agents had lower risks 
of pneumonia (UC patients), hospitalisation and severe COVID- 19 
(CD patients); this protective role against severe COVID- 19 confirms 
findings of previous studies.8,11,13 Due to the small subgroup of pa-
tients in combination therapy with anti- TNF agents and immunosup-
pressants, we are not able to draw conclusions about its reported 
potential negative impact.13 The potential protective role of anti- 
TNF agents could be due to their downregulation of ACE2 expres-
sion in the intestine,22 their known effects on cytokine storms,23 or 
to a general dampening of the inflammatory response during the hy-
perimmune phase of the infection.2
Our study did not find an association between salicylates and 
COVID- 19 outcomes, once confounders were eliminated through 
multivariable analysis. This finding is in apparent contrast to reports 
of an association between salicylate use and a negative course of 
SARS- CoV- 2 infection from the SECURE- IBD international regis-
try.11,13 This potential negative role of salicylates is a matter of de-
bate: besides the theoretical plausibility,24 it is possible that several 
biases led to this finding, including the fact that anti- TNF agents 
were used as a comparator.25 Our study also did not find any impact 
of corticosteroids, in contrast to earlier studies where these drugs 









F I G U R E  1   ROC curve analysis of the 
IG- IBD COVID- 19 index for the risk of 
moderate- to- severe COVID- 19. A, UC 
patients. B, CD patients [Colour figure can 
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were negative factors for a worse outcome of COVID- 19 with a pos-
sible dose- dependent effect.8,11,14 However, the close association 
with disease activity and the lack of complete information about 
doses, reasons for taking these drugs and duration of therapy do not 
allow us to draw firm conclusions.
Using the risk factors identified in multivariable analysis for 
moderate- to- severe COVID- 19, we developed two indices of the risk 
for adverse outcomes in UC and CD patients. In our models, scores 
≥0.9 for UC patients and ≥2.20 for CD patients were the best cut- 
offs to identify those at higher risk. These indices could be useful 
in identifying IBD patients who could be prioritised for vaccination, 
especially in contexts where vaccines are scarce and when boosters 
will become necessary. However, due to the relatively low absolute 
number of IBD patients at higher risk of adverse outcomes, these 
indices could have a relatively poor diagnostic accuracy. Moreover, 
they need to be validated before they are used in clinical practice.
This study reports the findings from a large cohort of consecu-
tive IBD patients with COVID- 19 from a single country, where the 
management of IBD is relatively homogeneous. The participation 
of many IG- IBD centres across Italy makes our study a reliable por-
trait of the Italian situation of IBD patients infected by SARS- CoV- 2. 
Importantly, we evaluated UC and CD patients separately since UC 
and CD are different diseases, with different therapies and different 
indices to assess disease activity. Indeed, in our study, the UC and 
CD populations differed significantly in terms of baseline character-
istics, including therapies, and symptoms of SARS- CoV- 2 infection, 
so we analysed them separately for COVID- 19 risk factors. Instead, 
none of the prior studies on COVID- 19 outcomes in IBD patients 
distinguished between UC and CD patients. Finally, the fact that 
we adjusted our risk factor analyses for several confounders should 
clarify some of the conflicting results reported so far.
Our study has some limitations. First, we cannot exclude the 
under- reporting of cases: some participating centres may not have 
included all their patients due to the voluntary referral, and asymp-
tomatic and mild forms of SARS- CoV- 2 infection may have been 
missed (mainly patients in remission or not under strict monitor-
ing). On the contrary, we also cannot exclude the over- reporting of 
asymptomatic and mild forms of SARS- CoV- 2 infection in patients 
under close follow- up (ie, patients in biological therapy). Our find-
ings can be extended only to other settings similar in social, cultural, 
political and economic backgrounds. Finally, the proposed indices to 
identify IBD patients at higher risk of adverse COVID- 19 outcomes 
should be validated before clinical implementation.
In conclusion, this study confirms that SARS- CoV- 2 generally has 
a mild course in IBD patients, and that the risk factors for moderate- 
to- severe COVID 19 are the same as observed in the general pop-
ulation. On the basis of these results, we feel that no additional or 
different precautions should be adopted for IBD patients. In partic-
ular, because we did not find any evidence for a negative effect of 
IBD therapies on the outcome of SARS- CoV- 2 infection, our study 
provides support for the recommendations of the European Crohn´s 
and Colitis Organisation,26 which state to not stop in advance med-
ications needed to maintain IBD in remission and to avoid flares 
due to discontinuation. The indices created here to identify UC and 
CD patients with a higher risk of adverse COVID- 19 outcomes may 
boost the effectiveness of ongoing and future vaccination programs 
and of future specific therapies for SARS- CoV- 2 by identifying a sub-
set of IBD patients who merit prioritisation.
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